E-Mail
The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2021 recipients of the Damon Runyon-Rachleff Innovation Award. Five initial grants of $400,000 over two years were awarded to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer. Each project will have the opportunity for up to two additional years of funding (four years total for $800,000). This year, Stage 2 continuation support was granted to two awardees who demonstrated significant progress on their proposed research during the first two years of the award.
The Damon Runyon-Rachleff Innovation Award funds cancer research by exceptionally creative thinkers with high-risk/high-reward ideas who lack sufficient preliminary data to obtain traditional funding. The awardees are selected through a highly competitive and rigorous process by a scientific committee
Carl Zimmer, The New York Times
Published: 07 Jan 2021 07:28 PM BdST
Updated: 07 Jan 2021 07:28 PM BdST Research scientist Hong Xie holds a box of samples at a genome sequencing lab at the University of Washington in Seattle on April 15, 2020. With no robust system to identify a dangerous new variant of the coronavirus, experts warn that the United States is woefully ill-equipped to track its spread, leaving health officials blind as they try to combat the grave threat. Ruth Fremson/The New York Times
With no robust system to identify genetic variations of the coronavirus, experts warn that the United States is woefully ill-equipped to track a dangerous new mutant, leaving health officials blind as they try to combat the grave threat.
New president of EuChemS Floris Rutjes
Floris Rutjes, a synthetic organic chemist who is vice-dean at Radboud University in the Netherlands and also vice-president of the Royal Netherlands Chemical Society, took the helm of the European Chemical Society (EuChemS) on 1 January. Rutjes assumed his new role as head of the umbrella organisation for European chemical societies after being elected at the EuChemS general assembly in Bucharest, Romania in October 2020. He succeeds Pilar Goya, a research professor at the Spanish Research Council’s Institute of Medical Chemistry in Madrid, and will remain in post until the end of 2023.
Rutjes’ work focuses on developing new and sustainable synthesis methodology, designing and synthesising biologically active small molecules, as well as new probes for bio-orthogonal conjugation, and continuous flow chemistry in microreactor systems. He earned a PhD in organic chemistry from the University of Amsterdam in 1993, and did his postdoctoral wor
U S Is Blind to Virus Variant Swamping British Hospitals, Scientists Warn msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021 GMT
WOBURN, Mass. (BUSINESS WIRE) Jan 5, 2021
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 39 th annual J.P. Morgan Healthcare conference.
Mr. Lucchino’s presentation will take place on Wednesday, January 13 th at 7:30 a.m. ET. The presentation will be followed by a question and answer session to be held at 8:00 a.m. ET. A live webcast of both the presentation and the breakout session can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A repl